Niki BioSolutions, Inc 6-K/A, filed Mar 26, 2026
Niki BioSolutions, Inc. (NIKI)
About this 6-K/A
Niki BioSolutions, Inc filed this 6-K/A on March 26, 2026.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K/A
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2026
Commission File Number: 001-38764
Aptorum Group Limited
17 Hanover Square
London W1S 1BN, United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
On June 22, 2025, Aptorum Group Limited, a Cayman Islands exempted company with limited liability (“Aptorum”, “APM,” “Aptorum Group” or the “Company”) filed the original report on Form 6-K (the “Initial Report”) to report that it and DiamiR Biosciences Corp., a Delaware corporation (“DiamiR”), entered into an Agreement and Plan of Merger on July 14, 2025, (the “Merger Agreement”), pursuant to which, among other matters, Aptorum will form a direct, wholly owned subsidiary in the state of Delaware (“Merger Sub”), which will merge with and into DiamR, with DiamiR surviving as a wholly owned subsidiary of Aptorum , and the surviving corporation of the merger with the Merger Sub (the “Merger”). Aptorum following the Merger is referred to herein as the “Combined Company.”
Concurrently with the execution of the Merger Agreement, DiamiR and Aptorum Therapeutics Limited, a wholly owned subsidiary of the Company (“Aptorum Therapeutics”), entered into a management services agreement (the “Management Services Agreement”). In addition, concurrently with the execution of the Merger Agreement, DiamiR, DiamiR LLC, a wholly owned subsidiary of DiamiR, the Company and Aptorum Therapeutics entered into an intellectual property license agreement (“Licensing Agreement”), pursuant to which DiamiR and DiamiR LLC shall license on a non-exclusive basis their respective intellectual properties to Aptorum Therapeutics in exchange for upfront and periodic payments and royalties until the earlier of the closing of the Merger or December 31, 2025.
As set forth in the Initial Report, the Termination Date for the Merger was initially set at December 31, 2025; the Management Services Agreement and Licensing Agreement were also set to expire on December 31, 2025. As the parties continue to work towards satisfying the closing conditions for the Merger, they agreed to extend the Termination Date and other agreements to June 30, 2026. The parties signed an amendment to the Management Services Agreement reflecting the extended term (the “Amendment”).
The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, which is attached hereto as Exhibit 10.3 and is incorporated herein by reference.
Non-Solicitation
This report is not a notice of shareholders meeting or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transactions and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Aptorum or DiamiR, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Additional Information about the Transactions and Where to Find It
In connection with the Merger and related transactions, Aptorum filed a registration statement on Form S-4 (File No. 333-290742) with the SEC on October 6, 2025 and will mail notices of shareholders meeting and other relevant documents to its shareholders. Investors and security holders of Aptorum are advised to read, when available, the Form S-4, and amendments thereto, the notice to shareholders, and amendments thereto, in connection with Aptorum’s solicitation of proxies for its shareholder’ meeting to be held to approve the transactions described herein because the notice to shareholders will contain important information about the transactions and the parties to the transactions. The notices to shareholders will be mailed to Aptorum’s shareholders as of a record date to be established for voting on the proposed transactions. Shareholders will also be able to obtain copies of the notice, without charge, once available, at the SEC’s website at www.sec.gov or by directing a request to: 17 Hanover Square, London W1S 1BN, United Kingdom, attention: Ian Huen.
This Form 6-K shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. A copy of Aptorum’s registration statement on Form S-4 can be viewed on the SEC’s website.
Financial Statements and Exhibits.
Exhibits.
The following exhibits are attached.
| (1) | Incorporated by reference to the Current Report on Form 6-K filed on July 22, 2025 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: March 26, 2026
| Aptorum Group Limited | ||
| By: | /s/ Ian Huen | |
| Ian Huen | ||
| Chief Executive Officer | ||
Exhibit 10.3
AMENDMENT No. 2 TO
MANAGEMENT SERVICES AGREEMENT
This Amendment dated as of March 25, 2026, (the “Amendment”), is by and between DiamiR Biosciences Corp. a Delaware, U.S., incorporated company (the “Service Provider”) and Aptorum Therapeutics Limited (“Aptorum Therapeutics,” a Cayman Islands exempted company with limited liability, Service Provider and Aptorum Therapeutics, each a “Party” and collectively, the “Parties”).
BACKGROUND
WHEREAS, the Parties entered into that certain Management Services Agreement dated July 14, 2025 (as amended on December 2, 2025, the “MSA”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the MSA.
WHEREAS, the Parties seek to extend the term of the MSA;
WHEREAS, this Amendment constitutes a written agreement signed by the necessary parties in order to effectuate the amendments to the MSA specified below.
NOW, THEREFORE, in consideration of the foregoing and the respective covenants and agreements set forth herein, the parties hereto agree as follows:
| 1. | Section 4.01 Term of the MSA is amended as follows: |
“The Agreement shall commence on the date hereof and shall continue until the earlier (i) the closing of the transaction(s) contemplated by the Definitive Agreements; or (ii) June 30, 2026.”
| 2. | Except as herein above amended, the terms and provisions of the Agreement shall remain in full force and effect. |
| 3. | This Amendment may be executed in any number of counterparts, each of which shall be considered an original for all purposes. |
| 4. | This Amendment shall extend to and be binding upon the heirs, executors, administrators, successors, and assigns of each of the parties hereto. |
[Signature Page Follows]
| DIAMIR BIOSCIENCES CORP. | ||
| By: | ||
Print Name: Title: |
Alidad Mireskandari Chief Executive Officer | |
| APTORUM THERAPEUTICS LIMITED | ||
| By: | ||
Name: Title: |
Ian Huen Chief Executive Officer | |